Mast Cell Tumors in Dogs: Skin Lumps Every Owner Should Know

By Emiel Maddens  ·  Reviewed in consultation with licensed veterinary professionals  ·  Updated June 2026  ·  10 min read

Photo by Alexander Mass on Unsplash

Mast cell tumors are the most frequently diagnosed malignant skin tumors in dogs, and every dog owner should be aware of their existence. These tumors arise from mast cells, a type of immune cell normally found in connective tissue throughout the body, particularly in the skin, respiratory tract, and gastrointestinal tract. While some mast cell tumors are relatively low-grade and carry excellent prognoses after surgical removal, others can be aggressive, spreading to lymph nodes and internal organs if not caught and treated early.

One of the most important facts about mast cell tumors is that they are master mimics. A mast cell tumor can look like a small, harmless bump, a raised wart-like growth, a soft lump under the skin, or an angry, inflamed mass. There is no way to reliably distinguish a mast cell tumor from a benign growth based on appearance alone, which is why veterinarians strongly recommend aspirating any new, changing, or suspicious lump on your dog. Early detection through routine screening and prompt diagnostic workup is the single most important factor in achieving a favorable outcome.

This guide covers the biology of mast cell tumors, how they are diagnosed and graded, treatment options ranging from surgery to chemotherapy, and what you can expect during your dog's care.

Understanding Mast Cells and Mast Cell Tumors

What Are Mast Cells?

Mast cells are immune cells that play an important role in the body's defense against parasites and in allergic and inflammatory responses. They are packed with granules containing bioactive substances, including histamine, heparin, proteolytic enzymes, and various cytokines. When mast cells are activated by allergens, parasites, or other triggers, they release these granules in a process called degranulation, which triggers local inflammation, increased blood vessel permeability, and recruitment of other immune cells. In their normal function, mast cells are essential components of the immune system. Problems arise when these cells undergo neoplastic transformation and begin proliferating uncontrollably, forming a mast cell tumor.

Why Mast Cell Tumors Are Dangerous

Mast cell tumors are dangerous for two primary reasons. First, the neoplastic mast cells retain their ability to degranulate, meaning the tumor can release large quantities of histamine and other inflammatory mediators into the surrounding tissue and bloodstream. This can cause localized swelling, redness, and a phenomenon called Darier's sign, where the tumor area swells and reddens when manipulated. In severe cases, systemic degranulation can lead to gastrointestinal ulceration, anaphylaxis, blood clotting abnormalities, and cardiovascular collapse. Second, high-grade mast cell tumors have significant metastatic potential, meaning they can spread to regional lymph nodes, spleen, liver, and bone marrow, making treatment far more challenging.

Breed Predispositions

Certain breeds carry a significantly higher risk of developing mast cell tumors due to genetic factors. Boxers are the most well-known predisposed breed, though interestingly, their mast cell tumors tend to be lower grade with a better prognosis than in many other breeds. Pugs, Boston Terriers, and Bulldogs of all types also have elevated risk, and they tend to develop multiple cutaneous MCTs. Labrador Retrievers and Golden Retrievers, two of the most popular breeds worldwide, have moderately increased risk. Shar-Peis are notable for developing particularly aggressive mast cell tumors at a younger age than most other breeds. Flat-Coated Retrievers and Rhodesian Ridgebacks are also overrepresented. While mast cell tumors can occur in any breed, awareness of your dog's genetic predisposition helps guide appropriate screening vigilance.

Diagnosis: From Aspiration to Staging

Fine Needle Aspiration

Fine needle aspiration (FNA) is the critical first step in evaluating any suspicious skin mass. The procedure involves inserting a small gauge needle (typically 22 to 25 gauge) into the mass, applying gentle suction or using a non-aspiration technique, and collecting cells that are then spread onto a glass slide, stained, and examined under a microscope. Mast cell tumors are one of the easiest tumors to diagnose on cytology because their characteristic purple metachromatic granules are readily visible with standard Romanowsky-type stains. FNA can be performed in minutes during a routine office visit, usually without sedation, and provides a preliminary diagnosis that guides the urgency and type of further workup. If the aspirate confirms or strongly suggests a mast cell tumor, the next steps are tumor grading and staging.

Histopathological Grading

Once a mast cell tumor is surgically removed, histopathology provides crucial prognostic information through a grading system. The Patnaik grading system classifies MCTs into three grades: Grade I (well-differentiated, least aggressive), Grade II (intermediately differentiated), and Grade III (poorly differentiated, most aggressive). A newer two-tier Kiupel grading system simplifies classification into low-grade and high-grade based on specific histological criteria, including mitotic count, multinucleated cells, bizarre nuclei, and karyomegaly. The Kiupel system has shown superior prognostic accuracy in multiple studies. Additional prognostic markers include the Ki-67 proliferation index, AgNOR count, and c-kit mutation status, all of which help predict tumor behavior and guide treatment recommendations, particularly for Grade II tumors where prognosis is most variable.

Staging: How Far Has It Spread?

Staging determines whether the mast cell tumor has spread beyond its primary site, which profoundly influences treatment options and prognosis. The staging workup typically includes aspiration of the regional (draining) lymph node, even if it appears normal on palpation, because microscopic metastasis can be present in normal-sized lymph nodes. Abdominal ultrasound evaluates the spleen and liver for metastatic disease, with guided aspiration of any suspicious lesions. A complete blood count assesses for circulating mast cells (mastocytemia) and checks for abnormalities in blood cell counts that could indicate bone marrow involvement. A buffy coat smear may also be examined for mast cells. Bone marrow aspiration is performed when high-grade tumors or advanced-stage disease is suspected. The WHO clinical staging system ranges from Stage 0 (incompletely excised tumor without lymph node involvement) through Stage IV (tumor with distant metastasis or recurrence with metastasis).

The Role of c-kit Mutation Testing

The c-kit proto-oncogene encodes a receptor tyrosine kinase (KIT) that plays a key role in mast cell survival and proliferation. Mutations in c-kit are found in approximately 25 to 30 percent of mast cell tumors and are associated with increased tumor aggressiveness, higher recurrence rates, and poorer prognosis. Importantly, these mutations also predict responsiveness to tyrosine kinase inhibitor (TKI) drugs such as toceranib (Palladia) and masitinib (Kinavet). c-kit mutation testing is particularly valuable for intermediate-grade tumors where treatment decisions are complex, as a positive mutation may tip the balance toward recommending adjuvant therapy. Testing can be performed on the same tissue submitted for histopathology or on fresh tumor tissue collected at the time of surgery.

Any new or changing skin lump on your dog should be evaluated with fine needle aspiration to rule out mast cell tumors.

Photo by Anya Prygunova on Unsplash

Treatment Options for Mast Cell Tumors

Surgery: The Primary Treatment

Complete surgical excision with adequate margins remains the cornerstone of mast cell tumor treatment and is curative for many localized, low-grade to intermediate-grade tumors. The recommended surgical margin has been debated, but current evidence supports lateral margins of two centimeters and one fascial plane deep for most Grade I and II (or low-grade Kiupel) tumors. Wider margins may be needed for higher-grade tumors or tumors in locations where clean margins are difficult to achieve, such as the limbs, head, or perineum. Histopathologic evaluation of the surgical margins determines whether the tumor was completely removed. If margins are incomplete (tumor cells extend to the cut edge), options include revision surgery to remove additional tissue, radiation therapy to the tumor bed, or close monitoring depending on tumor grade and other prognostic factors.

Radiation Therapy

Radiation therapy is highly effective for mast cell tumors and is used in several clinical scenarios. For incompletely excised tumors where revision surgery is not feasible, radiation therapy to the surgical site can achieve long-term local control rates exceeding 90 percent for low-grade and many intermediate-grade tumors. Radiation is also used as a neoadjuvant treatment before surgery to shrink large or difficult-to-resect tumors. For inoperable tumors, palliative radiation protocols can reduce tumor size and relieve symptoms. Mast cell tumors are generally radiation-sensitive, meaning they respond well to conventional fractionated radiation protocols. Side effects are usually limited to the irradiated area and may include skin redness, moist desquamation, and temporary hair loss, all of which typically resolve within a few weeks after treatment completion.

Chemotherapy and Targeted Therapy

Chemotherapy is recommended for high-grade mast cell tumors, tumors with lymph node or distant metastasis, and as adjuvant therapy for intermediate-grade tumors with concerning prognostic indicators. Traditional chemotherapy protocols for MCTs typically use vinblastine and prednisone, administered in cycles over several months. This combination has shown improved survival times compared to surgery alone for high-risk tumors. Tyrosine kinase inhibitors (TKIs) have revolutionized MCT treatment, particularly for tumors with c-kit mutations. Toceranib phosphate (Palladia) is FDA-approved for canine mast cell tumors and works by blocking the KIT receptor, directly targeting the molecular driver of many MCTs. TKIs can be used as primary therapy for inoperable tumors, as adjuvant therapy after surgery, or as rescue therapy for recurrent disease. Side effects of TKIs may include gastrointestinal upset, decreased appetite, and protein loss in urine, but most dogs tolerate treatment well with appropriate dose adjustments.

Supportive Care During Treatment

Dogs with mast cell tumors benefit from supportive care aimed at managing the effects of histamine and other mediators released by the tumor. Antihistamines, specifically a combination of an H1 blocker (such as diphenhydramine or cetirizine) and an H2 blocker (such as famotidine), are commonly prescribed to counteract histamine effects on the skin and gastrointestinal tract. Proton pump inhibitors like omeprazole may be added for dogs at risk of gastrointestinal ulceration. Avoiding tumor manipulation is important, as rough handling can cause degranulation. During any surgical procedure involving a mast cell tumor, the surgical team takes precautions against intraoperative histamine release. Nutritional support, pain management, and regular monitoring of bloodwork are also integral parts of comprehensive MCT care.

Prognosis and Life After Diagnosis

Prognosis by Grade

Prognosis for mast cell tumors varies dramatically based on tumor grade and stage. Low-grade (Kiupel) or Grade I (Patnaik) tumors that are completely excised carry an excellent prognosis, with cure rates approaching 90 to 100 percent and median survival times often exceeding four to five years. Grade II tumors have the most variable prognosis, which is why additional prognostic markers like Ki-67 index and c-kit status are so valuable for this group. Median survival times for Grade II tumors range from about one year to over five years depending on these additional factors and whether the tumor is completely excised. High-grade (Kiupel) or Grade III (Patnaik) tumors carry the most guarded prognosis, with median survival times of approximately four to six months without treatment, though aggressive multimodal therapy can extend survival significantly in responsive cases.

Living with a Dog Diagnosed with MCT

A mast cell tumor diagnosis, while frightening, does not automatically mean a poor outcome. Many dogs with low-grade or intermediate-grade mast cell tumors are cured with surgery alone and go on to live normal lifespans. For dogs with higher-risk tumors requiring additional treatment, advances in chemotherapy, targeted therapy, and radiation have substantially improved outcomes over the past two decades. Maintaining regular veterinary follow-up is essential after MCT treatment, typically every three months for the first year and every six months thereafter, with thorough skin examinations and, when indicated, imaging to monitor for recurrence or new tumors. Dogs that have had one mast cell tumor are at increased risk for developing additional tumors at other sites.

Prevention Through Vigilance

While mast cell tumors cannot be prevented, early detection through regular skin examinations dramatically improves outcomes. Establish a routine of checking your dog's skin monthly, running your hands over every part of the body and noting any new lumps, bumps, or changes. For breeds with high MCT predisposition, consider more frequent checks. Do not adopt a wait-and-see approach with new lumps. The cost and discomfort of a fine needle aspiration is minimal compared to the consequences of allowing an undiagnosed mast cell tumor to grow and potentially spread. Early aspiration, early diagnosis, and early treatment give your dog the best possible chance for a positive outcome.

Mast Cell Tumors in Dogs FAQ

Q: How common are mast cell tumors in dogs?

Mast cell tumors are the most common malignant skin tumor in dogs, accounting for approximately 16 to 21 percent of all canine skin tumors. They can occur in any breed at any age, though the median age at diagnosis is about eight to nine years. Certain breeds, including Boxers, Pugs, Boston Terriers, and Shar-Peis, are at significantly higher risk due to genetic predisposition. Despite their frequency, many MCTs are caught early and treated successfully with surgery alone.

Q: Can you tell if a lump is a mast cell tumor by looking at it?

No, and this is one of the most important facts about mast cell tumors. They are often called the great imitators because they can look like virtually any type of skin growth, from a small, harmless-looking bump to a large, inflamed mass. Some appear as soft lumps under the skin, others look like wart-like growths, and some resemble insect bites. The only reliable way to identify a mast cell tumor is through fine needle aspiration, where cells are collected and examined under a microscope.

Q: What is the survival rate for dogs with mast cell tumors?

Survival rates depend heavily on tumor grade and stage. Dogs with completely excised low-grade mast cell tumors have cure rates approaching 90 to 100 percent, with many living normal lifespans. Intermediate-grade tumors have variable outcomes depending on additional prognostic factors, with median survival times ranging from one to five or more years. High-grade tumors carry a more guarded prognosis, with median survival times of four to six months without treatment, though aggressive therapy can significantly extend survival for some patients.

Q: Is chemotherapy effective for mast cell tumors in dogs?

Yes, chemotherapy can be very effective, particularly for high-grade tumors, tumors with metastatic disease, and intermediate-grade tumors with concerning prognostic markers. The vinblastine and prednisone protocol has demonstrated improved survival times in multiple studies. Tyrosine kinase inhibitors like toceranib (Palladia) have shown particularly strong results for tumors with c-kit mutations. Most dogs tolerate chemotherapy well, with side effects that are generally mild and manageable compared to human chemotherapy protocols.

Q: Should I aspirate every lump on my dog?

Yes, veterinary dermatologists and oncologists recommend aspirating any new or changing lump on your dog. Fine needle aspiration is quick, minimally invasive, inexpensive, and provides critical diagnostic information that visual inspection alone cannot. The peace of mind from confirming a benign diagnosis, or the early detection benefit of catching a malignant tumor before it spreads, far outweighs the minor inconvenience of the procedure. This recommendation is especially important for breeds with higher MCT predisposition.

Sources

Vail, D.M., Thamm, D.H., & Liptak, J.M. (2019). Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition. Elsevier.

Kiupel, M. et al. (2011). Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors. Veterinary Pathology, 48(1), 147-155.

London, C.A. & Thamm, D.H. (2013). Mast Cell Tumors. In Small Animal Clinical Oncology, 5th Edition. Elsevier.

Patnaik, A.K., Ehler, W.J., & MacEwen, E.G. (1984). Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Veterinary Pathology, 21(5), 469-474.

Blackwood, L. et al. (2012). European consensus document on mast cell tumours in dogs and cats. Veterinary and Comparative Oncology, 10(3), e1-e29.

Related Reading

• Skin Tags and Warts on Dogs, How to distinguish benign growths from those that need further evaluation
• Histiocytoma in Dogs, A benign tumor that can mimic mast cell tumors but resolves on its own
• Monthly Skin Check Guide, Step-by-step home examination to catch new lumps and bumps early
• Melanoma in Dogs, Another important skin cancer every dog owner should know about

Emiel Maddens

Founder of Vetified. Develops topical antifungal and antimicrobial formulations for companion animals. Vetified products are listed on DailyMed and manufactured through FDA-registered facilities in the United States.